BioCryst Pharmaceuticals, Inc. Forecast, price target & analysts
BioCryst Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
BioCryst Pharmaceuticals, Inc. Classifications & Recommendation
BioCryst Pharmaceuticals, Inc. Price Target
| Target Price | $18.87 |
| Price | $8.68 |
| Potential |
117.40%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target BioCryst Pharmaceuticals, Inc. 2027 .
The average BioCryst Pharmaceuticals, Inc. target price is $18.87.
This is
117.40%
register free of charge
$33.60
287.10%
register free of charge
$13.13
51.27%
register free of charge
|
|
| A rating was issued by 17 analysts: 15 Analysts recommend BioCryst Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BioCryst Pharmaceuticals, Inc. stock has an average upside potential 2027 of
117.40%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 874.84 | 723.79 |
| 94.10% | 17.27% | |
| EBITDA Margin | 39.14% | -70.15% |
| 13,668.55% | 279.25% | |
| Net Margin | 30.16% | -82.04% |
| 252.95% | 372.01% |
12 Analysts have issued a sales forecast BioCryst Pharmaceuticals, Inc. 2026 . The average BioCryst Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an BioCryst Pharmaceuticals, Inc. EBITDA forecast 2026. The average BioCryst Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 BioCryst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average BioCryst Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.21 | -2.33 |
| 381.40% | 292.56% | |
| P/E | negative | |
| EV/Sales | 3.72 |
13 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast for earnings per share. The average BioCryst Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
BioCryst Pharmaceuticals, Inc....
Current BioCryst Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Sep 08 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 06 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jul 07 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Sep 08 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 06 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jul 07 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 30 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
